PI
PI2.F Proteome Sciences plc
- Market cap
- EUR 1.71M
- P/E
- -
- P/B
- 920.52x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is PI2.F undervalued?
Graham numberThe Graham number of Proteome Sciences plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Proteome Sciences plc fundamental analysis
No fundamental analysis for Proteome Sciences plc yet.
Proteome Sciences plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Proteome Sciences plc
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that pro…
Full company profileProteome Sciences plc financial statements
Proteome Sciences plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.74M | 3.38M | 3.05M | 4.66M | 4.75M | 5.13M | 7.78M | 5.03M | 4.89M | 3.76M |
| Gross Profit | 1.55M | 2.20M | 1.87M | 2.95M | 2.59M | 2.96M | 4.77M | 1.65M | 670K | -81.0K |
| Operating Income | -2.69M | -1.81M | -1.37M | 299K | 549K | 412K | 1.73M | -1.62M | -2.35M | -2.67M |
| EBITDA | - | -1.48M | -1.14M | 388K | 714K | 625K | 2.01M | -1.14M | -1.52M | -1.74M |
| Net Income | -2.28M | -2.50M | -1.31M | 149K | 295K | 72.0K | 1.33M | -2.44M | -3.41M | -3.06M |
| EPS | - | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 9.70M | 7.48M | 7.03M | 8.36M | 9.09M | 10.0M | 12.4M | 11.5M | 9.11M | 8.26M |
| Total Liabilities | 9.89M | 10.0M | 10.8M | 12.0M | 12.5M | 12.8M | 13.3M | 14.5M | 15.7M | 17.8M |
| Shareholders' Equity | -189K | -2.56M | -3.82M | -3.65M | -3.36M | -2.78M | -843K | -3.07M | -6.62M | -9.53M |
| Cash & Short-term Investments | 2.88M | 908K | 958K | 799K | 2.21M | 2.39M | 3.99M | 2.03M | 1.13M | 781K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.99M | -1.70M | -504K | 20.0K | 1.58M | 793K | 2.14M | -481K | -826K | -46.0K |
| Capital Expenditure | 33.0K | 23.0K | 4.00K | 58.0K | 13.0K | 204K | 319K | 237K | 224K | 97.0K |
| Free Cash Flow | - | -1.72M | -508K | -38.0K | 1.57M | 589K | 1.82M | -718K | -1.05M | -143K |
| Ratios | ||||||||||
| ROA | -23.5% | -33.4% | -18.7% | 1.8% | 3.2% | 0.7% | 10.7% | -21.3% | -37.4% | -37.1% |
| Net Profit Margin | -83.1% | -73.9% | -43.1% | 3.2% | 6.2% | 1.4% | 17.0% | -48.6% | -69.7% | -81.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Proteome Sciences plc dividends
Proteome Sciences plc has not paid dividends in the last 10 fiscal years.
Who owns Proteome Sciences plc
- Insiders 18.52%
- Institutions 24.80%
- Public & others 56.68%
- Shares outstanding 351M
- Free float 220M
Proteome Sciences plc company profile
- Company name
- Proteome Sciences plc
- Ticker
- PI2.F
- ISIN
- GB0003104196
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Fiscal year end
- December
- Address
- Coveham House, Cobham, United Kingdom, KT11 3EP
- Phone
- 44 20 7043 2116
- Website
- proteomics.com
About Proteome Sciences plc
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM); SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. Proteome Sciences plc was incorporated in 1993 and is based in Cobham, the United Kingdom.
Proteome Sciences plc management
5- Mr. Christopher Donovan James Pearce Dip., MSIExecutive Chairman · born 1953
- Mr. Richard Paul DennisChief Commercial Officer & Executive Director · born 1958
- Mr. Stefan FuhrmannFinance Director
- David Van MeterChief Operations Officer
- Victoria Joanna BirseCompany Secretary